HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
Androgenetic alopecia is caused by DHT affecting hair growth. Finasteride and minoxidil are used to manage hair loss by blocking DHT and promoting hair growth.
The post argues that Post-Finasteride Syndrome (PFS) is likely not real and suggests symptoms may be due to mental health issues or the nocebo effect. The conversation includes personal experiences with finasteride, highlighting both positive and negative effects, and emphasizes consulting doctors and using reliable sources for medication.
The user has been treating hair loss with 1mg oral finasteride daily, 1mg topical minoxidil twice daily, and microneedling twice a week. They report improved hair quality and density but are still experiencing shedding.
A user has been on finasteride for 1.5 years and minoxidil for 2 years, experiencing worsening hair shedding, losing 300+ hairs per wash. They are concerned if this indicates the medicine isn't working and are seeking others' experiences.